Cantor Fitzgerald Keeps Their Buy Rating on GH Research (GHRS)
Cantor Fitzgerald analyst Joshua Schimmer has reaffirmed a Buy rating on GH Research (GHRS) with a price target of $25.00. Schimmer, a 5-star analyst with a 15.5% average return and 52.43% success rate, highlights that the consensus on GH Research is a Strong Buy, with an average price target of $29.75.
In a report released yesterday, Joshua Schimmer from Cantor Fitzgerald maintained a Buy rating on GH Research, with a price target of $25.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Schimmer is a 5-star analyst with an average return of 15.5% and a 52.43% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Cabaletta Bio, Palvella Therapeutics, and Rocket Pharmaceuticals.
Currently, the analyst consensus on GH Research is a Strong Buy with an average price target of $29.75.
